TY - JOUR
T1 - Nanoparticles and the blood-brain barrier
T2 - Advancing from in-vitro models towards therapeutic significance
AU - Mc Carthy, David J.
AU - Malhotra, Meenakshi
AU - O'Mahony, Aoife M.
AU - Cryan, John F.
AU - O'Driscoll, Caitriona M.
N1 - Publisher Copyright:
© 2014 Springer Science+Business Media New York.
PY - 2015/4
Y1 - 2015/4
N2 - The blood-brain barrier is a unique cell-based restrictive barrier that prevents the entry of many substances, including most therapeutics, into the central nervous system. A wide range of nanoparticulate delivery systems have been investigated with the aim of targeting therapeutics (drugs, nucleic acids, proteins) to the brain following administration by various routes. This review provides a comprehensive description of the design and formulation of these nanoparticles including the rationale behind individual approaches. In addition, the ability of currently available in-vitro BBB models to accurately predict the in-vivo performance of targeted nanoparticles is critically assessed.
AB - The blood-brain barrier is a unique cell-based restrictive barrier that prevents the entry of many substances, including most therapeutics, into the central nervous system. A wide range of nanoparticulate delivery systems have been investigated with the aim of targeting therapeutics (drugs, nucleic acids, proteins) to the brain following administration by various routes. This review provides a comprehensive description of the design and formulation of these nanoparticles including the rationale behind individual approaches. In addition, the ability of currently available in-vitro BBB models to accurately predict the in-vivo performance of targeted nanoparticles is critically assessed.
KW - Blood-brain barrier
KW - Drug delivery to the CNS
KW - In vitro models
KW - Targeted nanoparticles
KW - Transcytosis
UR - https://www.scopus.com/pages/publications/84936856083
U2 - 10.1007/s11095-014-1545-6
DO - 10.1007/s11095-014-1545-6
M3 - Article
C2 - 25446769
AN - SCOPUS:84936856083
SN - 0724-8741
VL - 32
SP - 1161
EP - 1185
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 4
ER -